Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood. 2011;117(9):2585–2595. doi: 10.1182/blood-2010-09-271437
   PubMed Web of Science ®Google Scholar
• Shimizu-Kohno K, Kimura Y, Kiyasu J, et al. Malignant lymphoma of the spleen in Japan: a clinicopathological analysis of 115 cases. Pathol Int. 2012;62(9):577–582. doi: 10.1111/j.1440-1827.2012.02844.x
   PubMed Web of Science ®Google Scholar
• Behdad A, Bailey NG. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014;138(10):1295–1301. doi: 10.5858/arpa.2014-0291-CC
   PubMed Web of Science ®Google Scholar
• Sreedharanunni S, Sachdeva MU, Malhotra P, et al. Role of blood and bone marrow examination in the diagnosis of mature lymphoid neoplasms in patients presenting with isolated splenomegaly. Hematology. 2015;20(9):530–537. doi: 10.1179/1607845415Y.0000000005
   PubMed Web of Science ®Google Scholar
• Falk S, Stutte HJ. Primary malignant lymphomas of the spleen. A morphologic and immunohistochemical analysis of 17 cases. Cancer. 1990;66(12):2612–2619. doi: 10.1002/1097-0142(19901215)66:12<2612::AID-CNCR2820661225>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Kehoe J, Straus DJ. Primary lymphoma of the spleen. clinical features and outcome after splenectomy. Cancer. 1988;62(7):1433–1438. doi: 10.1002/1097-0142(19881001)62:7<1433::AID-CNCR2820620731>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Baseggio L, Salles G, et al. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med. 2012;13(71):253–265.
   PubMedGoogle Scholar
• Ruchlemer R, Wotherspoon AC, Thompson JN, et al. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia. Br J Haematol. 2002;118(4):952–958. doi: 10.1046/j.1365-2141.2002.03716.x
   PubMed Web of Science ®Google Scholar
• Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol. 1997;15(1):52–60. doi: 10.1200/JCO.1997.15.1.52
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30(1–2):139–148. doi: 10.1016/j.beha.2016.07.004
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2014;93(3):449–458. doi: 10.1007/s00277-013-1900-4
   PubMed Web of Science ®Google Scholar
• Xing KH, Kahlon A, Skinnider BF, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol. 2015;169(4):520–527. doi: 10.1111/bjh.13320
   PubMed Web of Science ®Google Scholar
• Bairey O, Shvidel L, Perry C, et al. Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival. Cancer. 2015;121(17):2909–2916. doi: 10.1002/cncr.29487
   PubMed Web of Science ®Google Scholar
• Shimono J, Miyoshi H, Kiyasu J, et al. Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma. Br J Haematol. 2017;178(5):719–727. doi: 10.1111/bjh.14736
   PubMed Web of Science ®Google Scholar
• Howard MT, Dufresne S, Swerdlow SH, et al. Follicular lymphoma of the spleen: multiparameter analysis of 16 cases. Am J Clin Pathol. 2009;131(5):656–662. doi: 10.1309/AJCPF9V8XRDYWTIR
   PubMed Web of Science ®Google Scholar
• Koiso H, Yokohama A, Mitsui T, et al. Follicular lymphoma presenting with marked splenomegaly: report of three cases. Acta Haematol. 2012;128(1):47–52. doi: 10.1159/000337037
   PubMed Web of Science ®Google Scholar
• Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP, et al. The splenic form of mantle cell lymphoma. Eur J Haematol. 2002;68(1):12–21. doi: 10.1034/j.1600-0609.2002.00551.x
   PubMed Web of Science ®Google Scholar
• Lu CL, Tang Y, Yang QP, et al. Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases. Hum Pathol. 2011;42(12):1965–1978. doi: 10.1016/j.humpath.2011.01.034
   PubMed Web of Science ®Google Scholar
• Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722–1728. doi: 10.1001/jamaoncol.2016.6905
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi: 10.1016/0895-4356(92)90133-8
   PubMed Web of Science ®Google Scholar
• McClintock S, Ma Z-q, Rieger RH. Incorrect inference in prevalence trend analysis due to misuse of the odds ratio. Ann Epidemiol. 2016;26(2):136–140. doi: 10.1016/j.annepidem.2015.12.009
   PubMed Web of Science ®Google Scholar
• Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35–44. doi: 10.1002/sim.4780030106
   PubMed Web of Science ®Google Scholar
• Ollila TA, Olszewski AJ. Radiation therapy in primary testicular lymphoma: does practice match the standard of care? Leuk Lymphoma. 2018: Epub ahead of print; DOI:10.1080/10428194.10422018.11480776. PMID: 29966467.
   PubMed Web of Science ®Google Scholar
• Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69(345):81–86. doi: 10.1080/01621459.1974.10480131
   Web of Science ®Google Scholar
• Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol. 2012;87(11):E119–E122. doi: 10.1002/ajh.23314
   PubMed Web of Science ®Google Scholar
• Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322–328. doi: 10.1111/bjh.12036
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Sachanas S, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666–670. doi: 10.1182/blood-2018-02-833608
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the surveillance, Epidemiology, and end results database. Cancer. 2013;119(3):629–638. doi: 10.1002/cncr.27773
   PubMed Web of Science ®Google Scholar
• Starr AG, Caimi PF, Fu P, et al. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. Hematology. 2017;22(7):405–411. doi: 10.1080/10245332.2017.1279842
   PubMed Web of Science ®Google Scholar
• Shimono J, Miyoshi H, Kamimura T, et al. Clinicopathological features of primary splenic follicular lymphoma. Ann Hematol. 2017;96(12):2063–2070. doi: 10.1007/s00277-017-3139-y
   PubMed Web of Science ®Google Scholar
• Mollejo M, Rodriguez-Pinilla MS, Montes-Moreno S, et al. Splenic follicular lymphoma: clinicopathologic characteristics of a series of 32 cases. Am J Surg Pathol. 2009;33(5):730–738. doi: 10.1097/PAS.0b013e318193fcef
   PubMed Web of Science ®Google Scholar
• Lenglet J, Traulle C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma. 2014;55(8):1854–1860. doi: 10.3109/10428194.2013.861067
   PubMed Web of Science ®Google Scholar
• Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26(8):1895–1898. doi: 10.1038/leu.2012.72
   PubMed Web of Science ®Google Scholar
• Yoong Y, Kurtin PJ, Allmer C, et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin’s lymphoma. Leuk Lymphoma. 2001;42(6):1235–1241. doi: 10.1080/10428190127511
   PubMed Web of Science ®Google Scholar
• Clot G, Jares P, Gine E, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132(4):413–422. doi: 10.1182/blood-2018-03-838136
   PubMed Web of Science ®Google Scholar
• Bjorck E, Landgren O, Schoumans J, et al. Molecular cytogenetic approach to the diagnosis of splenic lymphoma: a case report of blastoid mantle cell lymphoma. Leuk Lymphoma. 2003;44(7):1229–1234. doi: 10.1080/1042819031000077061
   PubMed Web of Science ®Google Scholar
• Lunning MA, Stetler-Stevenson M, Silberstein PT, et al. Spontaneous (pathological) splenic rupture in a blastic variant of mantle cell lymphoma: a case report and literature review. Clin Lymphoma. 2002;3(2):117–120. doi: 10.3816/CLM.2002.n.018
   PubMedGoogle Scholar
• Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009;20(6):1080–1085. doi: 10.1093/annonc/mdn751
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. doi: 10.1200/JCO.2008.16.4558
   PubMed Web of Science ®Google Scholar